Efficacy of thermal ablation for treatment of biopsy‐confirmed high‐grade cervical precancer among women living with HIV in Kenya

Abstract

AbstractThe World Health Organization recommends thermal ablation (TA) as an alternative to cryotherapy within “screen‐and‐treat” cervical cancer programs in low‐ and middle‐income countries (LMICs), including among women living with HIV (WLWH). Data on TA efficacy among WLWH are limited, however. We conducted a clinical trial to evaluate efficacy of TA for treatment of biopsy‐confirmed cervical intraepithelial neoplasia grades 2 and 3 (CIN2/3) among WLWH in Kenya. Nonpregnant HPV‐positive WLWH age 25 to 65 years underwent colposcopy‐directed biopsy, and same‐day treatment with TA, if eligible. Women with biopsy‐confirmed CIN2/3 at baseline had colposcopy‐directed biopsies at 12 months to determine cure. A total of 376 participants underwent TA during the study period. At baseline, 238 (63.3%) had normal histology, 39 (10.4%) had CIN1, 15 (4.0%) had CIN2, 55 (14.6%) had CIN3, 7 (1.9%) had microinvasive cancer and 22 (5.6%) had indeterminate results. Twelve‐month follow‐up pathology results are available for 59 of 70 (84.3%) participants with CIN2/3 at baseline. Of these, 39 (66.1%, 95% CI 0.54‐0.99) had successful treatment, defined as biopsy‐confirmed CIN1 or normal findings, while 20 (33.9%, 95% CI 0.22‐0.46) had treatment failure, defined as persistent biopsy‐confirmed CIN2 or worse. Treatment failure was 23.1% (95% CI 0.17‐0.46) and 39.9% (95% CI 0.23‐0.51) among women with CIN2 and CIN3 at baseline, respectively. HIV‐positive women with CIN2/3 have high rates of treatment failure at 1‐year following thermal ablation. This highlights a significant limitation in the current WHO cervical cancer secondary‐prevention strategy and calls for strategies to optimize cervical precancer treatment in this population.